^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FANCA Q1307fs

    i
    Other names: FANCA, FA Complementation Group A, Fanconi Anemia Complementation Group A, Fanconi Anemia Group A Protein, FANCH, FACA, FAA, Fanconi Anemia Complementation Group H, Fanconi Anemia Type 1, Protein FACA, FA-H, FA1, FAH, FA
    Entrez ID:
    2175
    Related biomarkers:
    Mutation
    CNA
    Others
    2years
    Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report. (PubMed, Medicine (Baltimore))
    We report the first case of FANCA-mutated HCC that responded well to olaparib and low-dose cisplatin. This addressed the potential therapeutic role of DDR gene mutation in HCC and the possible synergistic effect of PARP inhibitor and cisplatin. These findings highlight areas where further investigation and effort are needed.
    Journal • Tumor Mutational Burden • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • FANCA (FA Complementation Group A)
    |
    BRCA2 mutation • TMB-L • FANCA mutation • FANCA Q1307fs
    |
    Lynparza (olaparib) • cisplatin